Australia's Office of Drug Control has granted MGC Pharma a Cannabis Research Cultivation Permit, allowing the company to investigate whether its cannabis products can effectively treat cancer.
Under this permit, MGC Pharma will conduct botanical research in partnership with RMIT University with the aim of identifying novel cannabinoids and developing treatments for various medical conditions.
The company will test different cannabis strains for their cancer-fighting potential, starting with research on melanoma and prostate cancer.
This authorization follows a Cannabis Research Licence the company was granted in 2019.
MGC Pharma co-founder and managing director Roby Zomer said: “The grant of a
cannabis research cultivation permit is an important step forward as we
continue to broaden the potential application of our phytocannabinoid-derived medicinal products.
“Importantly, it also allows us to collaborate with other establishments to not
only improve existing genetics, but create new genetics for the Australian market.”
Seven days prior, the company was granted an import licence by the Australian Office of Drug Control to import medicinal cannabis from its European production facility.
